title: Incidence and risk factors for treatment failure with infliximab in psoriasis.
authors.affiliation: Department of Dermatology, Paul Sabatier University, Toulouse University Hospital, Toulouse, France.
authors.forename: H
authors.initials: H
authors.lastname: Escande
authors.forename: C Bulai
authors.initials: CB
authors.lastname: Livideanu
authors.forename: A
authors.initials: A
authors.lastname: Steiner
authors.forename: M
authors.initials: M
authors.lastname: Lahfa
authors.forename: M C
authors.initials: MC
authors.lastname: Marguery
authors.forename: J H
authors.initials: JH
authors.lastname: Mazereeuw
authors.forename: N
authors.initials: N
authors.lastname: Meyer
authors.forename: F G
authors.initials: FG
authors.lastname: Labadie
authors.forename: C
authors.initials: C
authors.lastname: Aquilina
authors.forename: R
authors.initials: R
authors.lastname: Viraben
authors.forename: P A
authors.initials: PA
authors.lastname: Gourraud
authors.forename: C
authors.initials: C
authors.lastname: Paul
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015994:Incidence; D000069285:Infliximab; D053208:Kaplan-Meier Estimate; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab